Compare SCM & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCM | HELP |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.2M | 214.5M |
| IPO Year | 2012 | N/A |
| Metric | SCM | HELP |
|---|---|---|
| Price | $8.41 | $4.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $51.50 |
| AVG Volume (30 Days) | 169.9K | ★ 567.3K |
| Earning Date | 05-11-2026 | 07-01-2026 |
| Dividend Yield | ★ 14.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $141.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.43 | $3.76 |
| 52 Week High | $15.39 | $8.55 |
| Indicator | SCM | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 52.71 |
| Support Level | N/A | $4.32 |
| Resistance Level | $9.85 | $4.75 |
| Average True Range (ATR) | 0.28 | 0.30 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 9.25 | 85.00 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.